Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Polatuzumab vedotin, marketed under the trade name POLIVY®, is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E) to B cells, resulting in anti-cancer activity against B-cell malignancies. In 2019, polatuzumab vedotin in combin...

Full description

Bibliographic Details
Main Authors: Randall C. Dere, Richard L. Beardsley, Dan Lu, Tong Lu, Grace H-W. Ku, Gabriel Man, Van Nguyen, Surinder Kaur
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
POLIVY ®
polatuzumab vedotin
antibody-drug conjugate
integrated summary of immunogenicity
diffuse large B- cell lymphoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1119510/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1119510/full

Similar Items